Merus's next shot is colorectal cancer
Petosemtamab's phase 2 data in this setting should come by the year end.
J&J goes straight into phase 3 in prostate
The company is to test its KLK2-targeting pasritamig in a late-line setting.
AbbVie broadens its telisotuzumab conjugate push
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
AbbVie makes a bigger bet on SEZ6
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
BioNTech's take on iza-bren enters the clinic
The latest projects newly into human trials include BNT3212.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
MacroGenics faces new competition
Duality takes its Adam9-targeting conjugate into the clinic.
